There are few disease-modifying therapeutics for neurodegenerative diseases, but
successes on the development of antisense oligonucleotide (ASO) therapeutics for spinal …

Alternative splicing of pre-mRNA increases genetic diversity, and recent studies estimate
that most human multiexon genes are alternatively spliced. If this process is not highly …

Scientific advances over the last four decades have steadily infused the Alzheimer's disease
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …

Alzheimer's disease (AD) represents a particular therapeutic challenge because its
aetiology is very complex, with dynamic progression from preclinical to clinical stages …

ABSTRACT RNA-based therapeutics have entered the mainstream with seemingly limitless
possibilities to treat all categories of neurological disease. Here, common RNA-based drug …

The severity of Alzheimer9s disease (AD) progression involves a complex interplay of
genetics, age, and environmental factors orchestrated by histone acetyltransferase (HAT) …

Gene therapy is making a comeback. With its twin promise of targeting disease etiology and
'long-term correction', gene-based therapies (defined here as all forms of genome …

Aging is a physiological and progressive phenomenon in all organisms' life cycle,
characterized by the accumulation of degenerative processes triggered by several …

Antisense oligonucleotides (ASOs) are single-stranded nucleic acid strings that can be used
to selectively modify protein synthesis by binding complementary (pre-) mRNA sequences …

Alzheimer's disease (AD) is the most frequent neurodegenerative disorder in the elderly,
occurring in approximately 20% of people older than 80. The molecular causes of AD are …